Korea delayed higher market value thresholds for delisting by six months, Newsis reported Friday after a government market review meeting.
KOSDAQ's special technology listing route reached 300 companies this month, Korea Exchange said Friday, according to Dailian.
Alteogen (196170) signed an exclusive option-license agreement with Novartis Pharma AG on September 2, the company said in a regulatory filing, covering its ALT-B4 recombinant human hyaluronidase platform, which converts intravenous biologics into under-the-skin injections.
Alteogen (196170) said in a filing that Korea's Ministry of Food and Drug Safety approved its Eylea biosimilar, Eyzenfy (code ALT-L9, ingredient aflibercept), on May 14, nearly 20 months after the company applied in September 2024.
Alteogen (196170) said Monday it will collect a $25.0m (~₩34.4bn) sales milestone from MSD International Business GmbH, triggered by U.S.
| Symbol | Last Price |
|---|---|
| 207940Samsung Biologics Co., Ltd. | ₩1,447,000 -2.0% |
| 068270Celltrion, Inc. | ₩188,100 +0.5% |
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |